Pharmaron

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier service provider for the life sciences industry. Founded in 2004, it has established research, development, and manufacturing service capabilities throughout the drug discovery, preclinical, and clinical development process across small molecules, biologics, and CGT products. It has over 25,000 employees and operations in China, the U.S., and the U.K., serving partners in North America, Europe, Japan, and China.

Pharmaron was founded in 2004. It has invested in its people and facilities and established a broad spectrum of research, development, and manufacturing service capabilities throughout the entire drug discovery, preclinical, and clinical development process across multiple therapeutic modalities, including small molecules, biologics, and CGT products. The company has over 25,000 employees and operations in China, the U.S., and the U.K., with a track record of delivering R&D solutions to partners in North America, Europe, Japan, and China.

• 2004

  Pharmaron founded, according to its official About Us page.

• Company grows to over 29,000 employees with operations in China, the U.S. and the U.K.

• Listed on the Shenzhen Stock Exchange under stock code 300759.SZ.

• Listed on the Hong Kong Stock Exchange under stock code 3759.HK.

Premier life science service provider offering comprehensive R&D and manufacturing capabilities throughout the drug discovery, preclinical, clinical development, and commercialization process.

• Laboratory Services

  Laboratory services supporting drug R&D with integrated DMPK, bioanalysis and central lab solutions.

• Chemistry, Manufacturing and Controls (CMC)

  Integrated chemistry manufacturing controls for APIs and drug products to satisfy global regulatory authorities.

• Clinical Development

  Clinical development services supporting drug candidates through Phase I–IV trials, ensuring safety, efficacy and regulatory compliance globally.

• Biologics & CGT

  Integrated biologics and cell & gene therapy services for bioprocess and clinical support.

• ADC & Other Bioconjugates

  End-to-end ADC discovery, development and GMP manufacturing services.

• Protein Degraders

  Comprehensive targeted protein degradation services.

• 2025

  Source

Read more

• 2022-01-10

  Pharmaron acquires Aesica Pharmaceuticals' Cramlington site[9]Pharmaron收购Aesica Pharmaceuticals的Cramlington厂区finanznachrichten.de

  Reported: 2022-01-10

  Pharmaron announced that it had acquired Aesica Pharmaceuticals Limited's Cramlington site in the United Kingdom from the Recipharm group. The site provides commercial active pharmaceutical ingredient manufacturing capacity.

• 2022-01-10

  Pharmaron acquires the Cramlington Site[10]Pharmaron收购克拉明顿厂区bio-itworld.com

  Pharmaron announced that it had acquired Aesica Pharmaceuticals Limited’s Cramlington Site from the Recipharm group.

• 2021-10-01

  Pharmaron promotes Katherine Lee to chief business officer[11]康龙化成晋升Katherine Lee为首席商务官finanznachrichten.de

  Reported: 2021-11-05

  Pharmaron promoted Katherine Lee to chief business officer, effective October 1, 2021. In the role, she will continue to lead and integrate the company’s global business development strategies and operations.

• 2021-03-01

  Pharmaron announces agreement to acquire the ABL site[12]Pharmaron宣布收购ABL生产基地的协议finanznachrichten.de

  Reported: 2021-03-01

  Pharmaron announced a definitive agreement to acquire Allergan Biologics Limited’s biomanufacturing site in Liverpool from AbbVie for US$118.7 million in cash. The transaction was expected to close in the second quarter of 2021, subject to customary closing conditions.

• 2020-11-09

  Pharmaron acquires Absorption Systems[13]Pharmaron收购Absorption Systemspharmaceutical-business-review.com

  Reported: 2020-11-09

  Pharmaron announced that it had acquired 100% of the equity of US-based Absorption Systems for up to $137.5 million in cash.

• 2019-11-28

  Pharmaron lists shares in Hong Kong[14]康龙化成在港交所上市finance.sina.com.cn

  Reported: 2019-11-28

  Pharmaron listed on the Hong Kong Stock Exchange on November 28, 2019, issuing 116.5 million shares and raising approximately HK$4.34 billion.

1. 1Life Science Contract Research Organization | Pharmaronpharmaron.com
2. 2Research And Development (R&D) Services | Pharmaronpharmaron.com
3. 3About Us | Pharmaronpharmaron.com
4. 4Our Global Site Locations | Pharmaronpharmaron.com
5. 5Pharmaronwikidata.org
6. 6康龙化成zh.wikipedia.org
7. 7实验室两名员工违章作业窒息死亡kfqgw.beijing.gov.cn
8. 8实验室两名员工违章作业窒息死亡m.bjnews.com.cn
9. 9Pharmaron收购Aesica Pharmaceuticals的Cramlington厂区finanznachrichten.de
10. 10Pharmaron收购克拉明顿厂区bio-itworld.com
11. 11康龙化成晋升Katherine Lee为首席商务官finanznachrichten.de
12. 12Pharmaron宣布收购ABL生产基地的协议finanznachrichten.de
13. 13Pharmaron收购Absorption Systemspharmaceutical-business-review.com
14. 14康龙化成在港交所上市finance.sina.com.cn